Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cancer Clinical Trials: Survival Used As Endpoint 12% Of Time, FDA Reports

Executive Summary

An FDA review of oncology drug approvals during the last eight years indicates that the survival endpoint has been used relatively infrequently to support a growing number of approved indications
Advertisement

Related Content

Progression-Free Survival Is Good Endpoint For Metastatic NSCLC, Cmte. Says
Progression-Free Survival Is Good Endpoint For Metastatic NSCLC, Cmte. Says
FDA Revising Accelerated Approval Standard In Oncology; Biomarkers Sought
Iressa Clears FDA: Phase IV Symptom Trial Will Be First Shot At Full Approval
Advertisement
UsernamePublicRestriction

Register

PS041952

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel